FDA Grants Clearance for Phase 1/2 Trial of eTIL KSQ-001EX in Solid Tumors
November 30th 2023The FDA has granted clearance for an investigational new drug application for a phase 1/2 safety lead-in trial investigating the engineered tumor-infiltrating lymphocyte KSQ-001EX in patients with melanoma, head and neck squamous cell carcinoma, and non–small cell lung cancer.
Read More
Increasingly Specialized Clinical Trials Accelerate Advances in NSCLC Management
November 27th 2023Subgroup analyses from non–small cell lung cancer clinical trials, such as the phase 3 POSEIDON and FLAURA2 trials, can help personalize treatment decisions with immunotherapy and targeted therapy based on individual mutational profiles.
Read More
Rutgers Research Summit Aims to Broaden Oncologic Perspectives Across New Jersey
November 24th 2023Andrew Evens, DO, MBA, MSc, highlights key points presented during the 2023 Rutgers Cancer Institute of New Jersey’s Annual Oncology Clinical Practice and Research Summit, the clinical implications of these presentations, and lymphoma treatment innovations that Rutgers Cancer Institute is providing to patients throughout New Jersey.
Read More
Selinexor Maintenance Leads to PFS Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer
November 22nd 2023Maintenance therapy with selinexor improved progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer, regardless of microsatellite instability status.
Read More
Toripalimab Approval Pioneers Immunotherapy Use in Nasopharyngeal Cancer
November 22nd 2023Nabil F. Saba, MD, FACP, and Shravan Kandula, MD, highlight the significance of the approval of toripalimab for nasopharyngeal carcinoma; key data from JUPITER-02 and POLARIS-02 trials; and how the addition of this agent to the treatment armamentarium heightens the importance of multidisciplinary collaboration.
Read More
Bayer Recalls Oral Larotrectinib Solution Because of Microbial Contamination
November 22nd 2023Bayer has voluntarily recalled 1 lot of the larotrectinib 20 mg/mL oral solution that is packaged in 100-mL glass bottles because of the presence of Penicillium brevicompactum contamination that was observed during ongoing, routine stability testing.
Read More
Emerging Therapeutic Targets Are Expanding the CLL Treatment Armamentarium
November 21st 2023Bhagirathbhai Dholaria, MBBS, discusses limitations in the current CLL standards of care that necessitate more effective therapies; BTK inhibitors and degraders on the horizon for this population; and the potential future role of CAR T-cell therapy for patients with CLL.
Read More
Refining Treatment Approaches Remains a Priority in High-Risk MCL
November 20th 2023Andre Goy, MD, discusses the agents that are currently available for the treatment of patients with relapsed/refractory mantle cell lymphoma, explains the prevalence of high-risk features in this population, and emphasizes the importance of enrolling patients into clinical trials to move the needle forward.
Read More
Rucaparib Receives EC Approval for Advanced Ovarian Cancer
November 20th 2023The European Commission has approved rucaparib as first-line maintenance therapy for patients with advanced ovarian cancer, regardless of BRCA mutation status, who have responded following the completion of frontline platinum-based chemotherapy.
Read More
Tebentafusp Sustains OS Benefit in Previously Untreated, Metastatic Uveal Melanoma
November 20th 2023Paul Nathan, MBBS, PhD, MRCP, discusses the differences between cutaneous melanoma and uveal melanoma that have led to unique unmet needs for patients with the latter malignancy; updated findings from the IMCgp100-202 trial; and how these findings may influence future clinical practice.
Read More
Regulatory Decisions and Research Boost Management Strategies for Hematologic Malignancies
November 15th 2023Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis, the importance of chronic graft-vs-host disease awareness in patients with myeloid malignancies receiving transplant, and unmet needs for patients with chronic myelomonocytic leukemia.
Read More
Durvalumab Plus Chemo Wins Approval in China For Advanced/Metastatic Biliary Tract Cancer
November 14th 2023China’s National Medical Products Administration has approved durvalumab plus gemcitabine and cisplatin for frontline use in adult patients with locally advanced or metastatic biliary tract cancer.
Read More
Interim Management Strategies Could Aid Patients With Advanced NSCLC Awaiting Biomarker Test Results
November 13th 2023Stephen V. Liu, MD, discusses strategies for treatment and disease management for patients with advanced non–small cell lung cancer who are awaiting biomarker test results.
Read More
Phase 1 Data Support Further Investigation of RMC-6236 in KRAS-Mutant NSCLC
November 7th 2023Kathryn C. Arbour, MD, discusses the unique mechanism of action of RMC-6236, the preliminary efficacy and safety findings for this agent in patients with KRAS-mutant NSCLC, and future directions for the RMC-6236-001 trial.
Read More
BCMA-Directed Therapies Broaden Myeloma Arsenal and Could Reshape Earlier Lines of Treatment
November 6th 2023Jesus Berdeja, MD, discussed considerations when choosing between bispecific antibodies and CAR T-cell therapy for patients with multiple myeloma, clinical trials that may move CAR T-cell therapy into earlier lines, and research with agents directed at targets other than BCMA.
Read More
Strategic Active Surveillance Methods Drive Patient-Focused Prostate Cancer Care
November 3rd 2023Active surveillance can provide eligible patients with low-risk prostate cancer the opportunity to defer or avoid treatment and instead opt for routine monitoring of their disease; however, challenges arise when determining which patients should be eligible for this approach and how to maintain patient and provider protocol compliance.
Read More
Bladder Cancer Programs Offer Patients Comprehensive and Cutting-Edge Care
November 3rd 2023Gautam Jayram, MD, discusses current standards of care in the bladder cancer treatment arena, novel therapies under investigation in clinical trials that may expand the arsenal of available treatment strategies, and emphasizes the importance of implementing bladder cancer programs.
Read More
Standards of Care and Novel Therapies Converge to Propel Advances in Follicular Lymphoma
November 3rd 2023Christopher R. Flowers, MD, MS, and colleagues shed light on recent updates in the treatment armamentarium for follicular lymphoma and highlight ongoing investigations of novel agents and combinations.
Read More
Zenocutuzumab Generates Durable Responses in Advanced NRG1+ NSCLC
November 1st 2023Zenocutuzumab elicited clinical activity with a tolerable safety profile in patients with advanced non–small cell lung cancer harboring NRG1 fusions, including those with prior afatinib exposure, according to findings from the ongoing, phase 1/2 eNRGy trial.
Read More
Tazemetostat/Lenalidomide/Rituximab Regimen Enters Phase 3 Research in R/R Follicular Lymphoma
November 1st 2023Steven I. Park, MD, discusses the unique design of the SYMPHONY-1 trial, the importance of enrolling patients to the phase 3 portion of the study, and why tazemetostat in combination with lenalidomide and rituximab could represent an effective and tolerable therapeutic option for frail or older patients with relapsed/refractory follicular lymphoma.
Read More
Emerging Therapeutic Targets Shape Testing and Treatment Decisions in SCLC and NSCLC
October 31st 2023Apar Kishor Ganti, MD, discusses molecular targets to test for in lung cancer; treatment approaches for small cell lung cancer; and immunotherapy options for patients with metastatic non–small cell lung cancer in the frontline setting and beyond.
Read More
EMA Validates Application for Frontline Nivolumab Plus Chemo in Advanced Urothelial Cancer
October 30th 2023The European Medicines Agency has validated a type II variation application for the first-line combination of nivolumab and cisplatin-based chemotherapy for adult patients with unresectable or metastatic urothelial carcinoma.
Read More
Expanding Immunotherapy Armamentarium Propels Personalized HCC Treatment Approaches
October 28th 2023Richard Kim, MD, discusses the range of systemic treatment options available for patients with unresectable hepatocellular carcinoma and the importance of assessing patients for high-risk disease criteria before beginning any systemic treatment.
Read More
FDA Grants Fast Track Designation to ONCT-534 for Relapsed/Refractory mCRPC
October 27th 2023The FDA has granted fast track designation to the dual-acting androgen receptor inhibitor ONCT-534 for the treatment of patients with relapsed/refractory, metastatic castration-resistant prostate cancer that is resistant to approved androgen receptor pathway inhibitors.
Read More
Bezuclastinib Plus Sunitinib Shows Encouraging Safety and Efficacy Profile in R/R Second-Line GIST
October 25th 2023The combination of bezuclastinib and sunitinib had a tolerable safety profile and demonstrated early signals of clinical activity in patients with gastrointestinal stromal tumor.
Read More